登录 | 注册    关注公众号  
微信公众号
搜索
 >  经MALS验证的蛋白>HVEM >HVM-H82F6

Biotinylated Human HVEM / TNFRSF14 Protein, Fc,Avitag™ (MALS verified)

热销产品推荐:

利用生物素-链霉亲和素系统的高特异性和高灵敏度的结合特性,可将生物素化蛋白与链霉亲和素相关产品联合应用于各类实验,与非生物素体系相比,检测速度更快、结合能力更强、非特异背景更低。

分子别名(Synonym)

TNFRSF14,ATAR,HVEA,HVEM,LIGHTR,TR2,CD270

表达区间及表达系统(Source)

Biotinylated Human HVEM, Fc,Avitag (HVM-H82F6) is expressed from human 293 cells (HEK293). It contains AA Leu 39 - Val 202 (Accession # Q92956-1 ).

Predicted N-terminus: Leu 39

Request for sequence

蛋白结构(Molecular Characterization)

HVEM Structure

This protein carries a human IgG1 Fc tag at the C-terminus, followed by a Avi tag (Avitag™)

The protein has a calculated MW of 45.5 kDa. The protein migrates as 55-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

标记(Labeling)

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

蛋白标记度(Protein Ratio)

Passed as determined by the HABA assay / binding ELISA.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>95% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH7.5 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

HVEM SDS-PAGE

Biotinylated Human HVEM, Fc,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-MALS

HVEM SEC-MALS

The purity of Biotinylated Human HVEM, Fc,Avitag(Cat. No. HVM-H82F6) is more than 90% and the molecular weight of this protein is around 100-120 kDa verified by SEC-MALS.

Report

 

活性(Bioactivity)-ELISA

HVEM ELISA

Immobilized Human LIGHT, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. LIT-H5256) at 2 μg/mL (100 μL/well) can bind Biotinylated Human HVEM, Fc,Avitag (Cat. No. HVM-H82F6) with a linear range of 0.6-39 ng/mL (QC tested).

Protocol

HVEM ELISA

Immobilized Biotinylated Human HVEM, Fc,Avitag (Cat. No. HVM-H82F6) at 5 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human CD160 Protein, His Tag with a linear range of 1-78 ng/mL (Routinely tested).

Protocol

背景(Background)

Herpesvirus entry mediator (HVEM) is also known as TNFRSF14, TR2 (TNF receptorlike molecule) and ATAR (another TRAF associated receptor), is a type I membrane protein belonging to the TNF/NGF receptor superfamily. HVEM expression has been detected in peripheral blood T cells, B cells, monocytes and in various tissues enriched in lymphoid cells. The extracellular domain of HVEM has been shown to interact directly with the herpes simplex virus envelope glycoprotein D (gD). Two TNF superfamily ligands, including the secreted TNFβ (lymphotoxin α) and the membrane protein LIGHT (lymphotoxins, exhibits inducible expression, and competes with HSV glycoprotein D for HVEM, a receptor expressed by T lymphocytes), have been shown to be the cellular ligands for HVEM. Besides HVEM, LIGHT can also interact with LTβR, the receptor for lymphotoxin αβ heterotrimer. The role of the HVEM LIGHT /LTβ receptor ligand pair in immune function and herpesvirus pathobiology remains to be elucidated.

 

 
货号/价格
产品推荐
文档
联系电话:
400-682-2521(全国)
010-53681107(北京)
021-31168505(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
HVEM靶点信息
英文全称:Tumor necrosis factor receptor superfamily member 14
中文全称:肿瘤坏死因子受体超家族成员14
种类:
上市药物数量:0详情
临床药物数量:0详情
最高研发阶段:临床前
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定